A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Trial Profile

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs KITE 718 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms HERMOSA-1
  • Sponsors Kite Pharma
  • Most Recent Events

    • 17 Aug 2017 Results (n=17) published in a Kite Pharma Media Release.
    • 17 Aug 2017 According to a Kite Pharma media release, results from this study were published in the Journal of Clinical Oncology.
    • 03 Jan 2017 According to a Kite Pharma media release, the company has submitted an Investigational New Drug (IND) application for KITE-718.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top